Mar 8: Mumbai-based pharma major Lupin Ltd on Thursday announced the signing of an agreement with CSIR-National Chemical Laboratory (CSIR-NCL, Pune) and Department of Science and Technology, (DST, Delhi) for conducting research on a continuous purification process development of a biosimilar monoclonal antibody therapeutic.
Monoclonal antibodies represent the most important biopharmaceutical product class, serving the high-demand treatment area of immuno-oncology diseases.
Through this research collaboration, CSIR-NCL and Lupin would collaboratively work towards the development of a novel continuous purification process for manufacturing a biosimilar monoclonal antibody therapeutic (mAb). The process development team of CSIR-NCL lead by Dr. Rahul Bhambure will work in collaboration with the team of Lupin for developing the target process, said Ashwini Kumar Nangia, Director of CSIR-NCL.
Speaking about the partnership, Rustom Mody, Senior Vice President and Head – R&D, Biotechnology, Lupin, said, “Biotech is one of Lupin’s key growth drivers and we are committed to advancing our biotech R&D capabilities through strategic partnerships. Our collaboration with a premier institution like CSIR is an exemplary industry-academia collaboration that can further the development and commercialisation of biologics and biosimilars for a better and more affordable healthcare to customers across the globe.”
Lupin shares were trading at Rs 764.65, up 0.53% from the previous closing of Rs 760.60, on BSE at 11.55 am today.